

1 **TITLE:** Incidence and Predictors of Recurrent Pericarditis in Systemic Lupus Erythematosus

2

3 **AUTHORS:** Yoo Jin Kim, MD MS^{1*}, Jana Lovell, MD^{2*}, Alaa Diab, MD MPH², Laurence S.

4 Magder, PhD MPH³, Daniel Goldman, PhD MCS⁴, Michelle Petri, MD MPH⁴,

5 Andrea Fava, MD⁴, Luigi Adamo, MD PhD²

6

7 **AFFILIATIONS:**

8 1. Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD

9 2. Division of Cardiology, Department of Medicine, Johns Hopkins University, Baltimore, MD

10 3. Department of Epidemiology & Public Health, University of Maryland School of Medicine,
11 Baltimore, MD

12 4. Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore,
13 MD

14 * These authors contributed equally to this work

15 These authors co-directed this work

16

17 **CORRESPONDING AUTHORS:**

18 Dr. Luigi Adamo & Dr. Andrea Fava

19 Division of Cardiovascular Medicine & Rheumatology, Department of Medicine

20 Johns Hopkins University, Baltimore, MD

21 Email: ladamo2@jhmi.edu & afava1@jhmi.edu

22

23 **ABSTRACT**

24 **IMPORTANCE:** Pericarditis is the most common cardiac manifestation of Systemic Lupus
25 Erythematosus (SLE) and known to recur among patients. Yet, the prevalence and risk factors of
26 recurrent pericarditis in SLE patients are unknown.

27 **OBJECTIVE:** Determine the frequency and risk factors for the recurrence of pericarditis in
28 patients with SLE.

29 **DESIGN:** Retrospective analysis of a well-characterized, prospective cohort of SLE patients
30 enrolled between 1988 and 2023.

31 **SETTING:** A single-center cohort study of a diverse group of SLE patients treated at a tertiary
32 medical center.

33 **PARTICIPANTS:** Patients diagnosed with pericarditis (n=590) among those enrolled in the
34 Hopkins Lupus Cohort (n=2931).

35 **MAIN OUTCOME:** Re-occurrence of pericarditis. The SELENA revision of the SLE Disease
36 Activity Index (SLEDAI) was used to define pericarditis. Clinical information was examined for
37 all follow-up encounters after the first episode of pericarditis. Pericarditis that occurred at least
38 six weeks after the first recorded episode was defined as “Recurrent”.

39 **RESULTS.** Of 2931 patients within the cohort, 590 had a history of pericarditis. In 3.4% of
40 patients, the diagnosis of pericarditis was confirmed via electrocardiogram (EKG) or dedicated
41 imaging, with 100% concordance between clinical and data-based diagnoses. During a median
42 follow-up of 7 years (IQR: 3 – 14), 20% (n=120) of patients experienced recurrent pericarditis
43 (recurrence rate \approx 0.05 per person-year of follow-up). Most patients (51%) experienced only one
44 recurrence, whereas 49% had ≥ 2 recurrences. In multivariate analysis, predictors of recurrence

45 included younger age (≥ 60 years vs. < 40 , RR 0.11 (0.04, 0.32), $P < .001$), treatment with
46 prednisone (≥ 20 mg vs. 0, RR 1.99 (1.17, 3.40), $P = 0.012$), active SLE disease (SLEDAI ≥ 3 vs.
47 0, RR 1.55 (1.21, 2.00), $P < .001$), and time since initial episode (3-10 years vs. < 1 , RR 0.32
48 (0.20, 0.52), $P < .001$).

49 **CONCLUSION AND RELEVANCE.** Recurrence is more likely to occur within one year of the
50 onset of pericarditis, and younger patients and those with uncontrolled disease are at greater risk
51 of recurrence. As in the general population, oral prednisone therapy is associated with a higher
52 chance of recurrence in SLE patients, with a dose-dependent effect. These findings set the basis
53 for future studies to define optimal treatment for recurrent pericarditis in SLE patients and
54 suggest that oral corticosteroids should be avoided when treating pericarditis.

55

56 INTRODUCTION

57 Pericarditis, defined as inflammation of the serosal sac that surrounds the myocardium, is
58 the most common cardiac manifestation of systemic lupus erythematosus (SLE) and noted in
59 about 20% of patients.¹⁻³ Patients can experience a spectrum of symptoms, ranging from mild
60 chest pain exacerbated by lying flat that is improved by leaning forward, to debilitating
61 symptoms of severe chest pain and dyspnea. Importantly, pericarditis is associated with
62 complications that include recurrence, myocarditis, and pericardial effusion.

63 In the general population, pericarditis recurs in approximately 30% of cases.⁴ Despite the
64 significant rate of recurrence, the mechanisms predisposing a subset of individuals to recurrence
65 remains unclear. Caforio and colleagues demonstrated the presence of serum anti-heart and anti-
66 intercalated-disk autoantibodies in patients with recurrent pericarditis.⁵ Furthermore, multiple
67 clinical trials have demonstrated the efficacy of immunosuppressive agents, such as
68 corticosteroids, in treating recurrent pericarditis, suggesting an immune-mediated mechanism.⁵⁻⁸
69 Recent pivotal studies further support this hypothesis, particularly implicating interleukin-1, a
70 pro-inflammatory cytokine of the innate immune system, in the pathophysiology of recurrent
71 pericarditis. Inhibitors targeting this pathway have proven effective in treating idiopathic
72 recurrent pericarditis across multiple randomized clinical trials.⁷⁻¹⁴

73 Given the broad immune dysregulation associated with SLE, patients may face greater
74 risk for recurrence due to possible overlapping immune-mediated mechanisms. However, the rate
75 of recurrence of pericarditis in SLE patients, its risk factors, and its association with various
76 treatments have not been characterized. To address this knowledge gap, we analyzed the Hopkins
77 Lupus Cohort, a large and well-characterized longitudinal cohort of SLE patients.

78

79 **METHODS**

80 **Patients.** The Hopkins Lupus Cohort is a longitudinal, prospective cohort of patients whose
81 diagnosis of SLE is confirmed before study enrollment.¹⁵ Patient history, laboratory testing, and
82 clinical information relevant to the classification of SLE and Systemic Lupus International
83 Collaborating Clinics / American College of Rheumatology Damage Index (SLICC/ACR SDI)
84 are recorded at the time of cohort entry.¹⁶ Cohort patients are followed quarterly at a minimum,
85 and clinical information and laboratory testing are updated at subsequent clinical visits. The
86 Hopkins Lupus Cohort is approved yearly by the Institutional Review Board of the Johns
87 Hopkins University School of Medicine. We identified patients who either had a history of
88 pericarditis at the time of cohort entry or were diagnosed with pericarditis during cohort
89 participation utilizing the criterion described below.

90
91 **Diagnostic criteria for pericarditis.** Pericarditis was diagnosed using the Safety of Estrogens in
92 Lupus Erythematosus National Assessment – SLE Disease Activity Index (SELENA-SLEDAI).¹⁷
93 One of the following criteria was necessary to be present for the diagnosis of pericarditis: (1)
94 pericardial pain, (2) auscultation of pericardial rub, (3) presence of pericardial effusion on
95 imaging, and (4) electrocardiogram (EKG) confirmation.^{17,18} Clinical information was examined
96 for all follow-up encounters after the first episode of pericarditis. “Recurrent” pericarditis was
97 defined as pericarditis that occurred at least six weeks after the first recorded episode. Multiple
98 recurrent episodes were identified if pericarditis occurred at least six weeks apart.

99
100 **Statistical analysis.** The analysis was based on cohort observations that occurred after the
101 patient’s first episode of pericarditis. For those with a history of pericarditis prior to cohort entry,

102 all cohort follow-up encounters were included. Cohort data were reformatted into a data set with
103 one record for each person-month of follow-up and used to calculate the rate of reoccurrence per
104 person-month given various patient characteristics or exposures. For ease of interpretation, rates
105 per person-month were converted to rates per person-year of follow-up. Rate ratios, confidence
106 intervals, and p-values were calculated using pooled logistic regression (a form of discrete
107 survival analysis) as implemented using generalized estimating equations (to account for the fact
108 that some participants experienced more than one recurrence).¹⁹ Analyses were performed using
109 SAS 9.4 (SAS Institute, Carey, North Carolina, USA).

110

111 **RESULTS**

112 **Patient characteristics.** Among the Hopkins Lupus Cohort (n=2931), 590 patients with a
113 history of pericarditis were included in analysis. Of these 590 patients, 451 (76%) patients
114 experienced their first episode of pericarditis prior to cohort entry, and the remaining 139
115 patients experienced their first episode while in the cohort. The majority of patients were women
116 (n = 535, 91%) and identified as Black (n = 303, 51%) (Table 1). The median duration of cohort
117 follow-up observed following the initial acute pericarditis episode was 6.7 years (IQR: 2.5 –
118 13.6).

119

120 **Overall rate of reoccurrence.** We observed a total of 5277 years of follow-up during which
121 time there were 278 recurrences of pericarditis for a rate of 0.053 per person-year of follow-up
122 (95% CI 0.047, 0.059). These events occurred in 120 different patients (20%), and 59 (49%) of
123 those patients experienced more than one episode of recurrence.

124

125 **Diagnostic criteria for pericarditis.** Patients were diagnosed with pericarditis based on the
126 SLEDAI criteria, which required the presence of at least one of the following: pericardial chest
127 pain, pericardial friction rub on auscultation, evidence of effusion, or findings on EKG. Most
128 patients were diagnosed based on symptomatic reports of pericardial chest pain (n = 567, 96%).
129 EKG or imaging studies were performed on a small subset of patients: EKG was conducted in 1
130 (0.2%), while transthoracic echocardiogram (TTE) or computed tomography (CT) imaging
131 findings demonstrated a pericardial effusion in 19 (3%) and 1 (0.2%) patients, respectively.
132 Importantly, when diagnostic data was collected in conjunction with symptomatic reports of
133 chest pain, the clinical diagnosis of pericarditis was confirmed 100% of the time.

134
135 **Risk factors for recurrent pericarditis.** Demographic, clinical, serologic, and treatment
136 characteristics were studied in univariate analysis to determine their association with recurrence
137 among patients with pericarditis (Table 2). Sex did not significantly impact recurrence rates.
138 Black race was associated with an increased risk of recurrent pericarditis (RR 1.72 (0.99, 2.97),
139 $P = 0.054$), and older age was associated with lower rates of recurrent pericarditis (40-49 years
140 [RR 0.58 (0.37, 0.90), $P = 0.016$] or 50-59 years [RR 0.25 (0.12, 0.53), $P < .001$] vs. 18-39 years).
141 Recurrence was more likely to occur within the first year from onset, after which the likelihood
142 of recurrence decreased (1-3 years vs. <1 RR 0.50 (0.32, 0.79), $P = 0.003$).

143 We evaluated the association of SLE disease activity with the risk of recurrence. We
144 found that patients with active lupus (SLEDAI scale score ≥ 3) experienced significantly
145 increased rates of recurrence (RR 2.34 (1.65, 3.30), $P < .001$). Systemic SLE activity beyond the
146 pericardium was associated with a risk of recurrence. Interestingly, patients with renal
147 involvement, such as proteinuria and nephrotic syndrome, as well as those with pulmonary

148 hypertension, had decreased recurrence rates ([Table 2](#)). Hypocomplementemia (C3 and C4) was
149 associated with increased rates of recurrence. However, a statistically significant association was
150 limited to C4 (Normal vs. low C4, RR 0.54 (0.37, 0.78), $P = 0.01$) rather than reduced C3
151 (Normal vs. low C3, RR 0.76 (0.52, 1.09), $P = 0.14$). Seropositivity for double-stranded DNA
152 (dsDNA) antibodies was associated with increased recurrence (RR 2.05 (1.40, 2.99), $P < .001$).

153 Finally, the therapies of SLE patients with recurrent pericarditis were assessed. Treatment
154 with oral prednisone at any dose was associated with increased rates of recurrence. Furthermore,
155 a dose-dependent association with recurrence was observed as the greatest rates of recurrence
156 were observed with the highest daily doses of prednisone ($\geq 20\text{mg}$) (RR 3.92 (2.31, 6.63), P
157 $< .001$). The use of hydroxychloroquine and other immunosuppressants did not affect recurrences,
158 and rates of pericarditis were lower after the year 2000. ([Table 2](#)).

159 To gain further insights into our findings, we performed a multivariate Cox hazard model
160 incorporating covariates identified as significant in the univariate analyses ($P < 0.05$) ([Table 2](#)).
161 The model identified younger age (< 40 years), time from first episode (< 1 year), daily
162 prednisone use ($\geq 20\text{mg}$), and clinically active disease (SLEDAI ≥ 3) as independent predictors
163 of recurrent pericarditis ([Figure 1](#)). Other variables that were found to be associated with
164 recurrence in the univariate analyses (low C4, anti-dsDNA, proteinuria, and history of
165 pulmonary hypertension) were not significantly associated with recurrence after adjustment for
166 other variables in the multivariable model.

167 **DISCUSSION**

168 In this study, we present a prospective analysis of recurrent pericarditis among SLE
169 patients. The rate of recurrent pericarditis among patients with SLE was 0.05 per year (120/590
170 patients, 20%). We found that whereas clinically active SLE and younger age are predictors of
171 recurrence, systemic involvement beyond the pericardium, such as the renal system (e.g.,
172 nephrotic syndrome and proteinuria) and pulmonary hypertension, may lead to decreased
173 recurrence. Importantly, prednisone use led to an increased risk of disease recurrence. These
174 findings expand our understanding of lupus pericarditis, underscore the need to reconsider using
175 oral prednisone to treat SLE flares involving the pericardium and identify the need for further
176 investigation of treatments for lupus pericarditis.

177 SLE is a complex disease characterized by broad immune dysregulation that is
178 considered the result of autoantibody production from irregularly activated and differentiated B
179 lymphocytes and abnormal interferon activity.²⁰ Similarly, the pathogenesis of recurrent
180 pericarditis in the general population has been presumed to be immune-mediated.⁸ Given the
181 increased potential for auto-immunity among patients with SLE, we hypothesized that patients
182 with SLE might experience an increased rate of recurrence following an acute episode of
183 pericarditis. Surprisingly, we found that the rate of pericarditis recurrence among patients with
184 SLE (20%) was lower than that reported in the general population (~33%).^{4,18}

185 Prior studies have examined risk factors for acute pericarditis among patients with SLE.
186 *Ryu et al.* reported predictors that include African-American ethnicity, anti-smooth muscle, anti-
187 DNA, hemolytic anemia, proteinuria, and Raynaud's phenomenon.³ However, to the best of our
188 knowledge, there have been no studies to date that have investigated the risk factors for
189 recurrence. We found that elevated SLEDAI scores, younger age at disease onset, recurrence

190 occurring within one year, and higher daily doses of prednisone were independently associated
191 with a two- to three-fold increased recurrence rate. This suggests that pericarditis recurrence
192 reflects both patient characteristics and treatment choices. Further, these findings suggest that
193 specific subgroups of patients with pericarditis may benefit from close monitoring and early
194 initiation of therapies proven to be effective for recurrent pericarditis, especially as recurrence is
195 more likely to occur within one year of the onset of pericarditis.²¹

196 The medical management of pericarditis for patients with SLE differs from that for the
197 general population. Although parenteral administration of glucocorticoids may be preferred to
198 prolonged oral administration to mitigate the risk of complications (e.g., avascular necrosis), oral
199 glucocorticoids are still considered for the treatment of SLE flares, including pericarditis.^{22,23} In
200 contrast, colchicine and non-steroidal anti-inflammatory drugs (NSAIDs) are preferred first-line
201 agents for the treatment of acute pericarditis in the general population.^{4,24,25} In fact, the
202 Investigation on Colchicine for Acute Pericarditis (ICAP) trial demonstrated that glucocorticoid
203 use is an independent risk factor for recurrence.²⁵ Furthermore, a meta-analysis of 7 studies,
204 which included 471 patients, confirmed these findings: not only did steroids increase the risk of
205 recurrent pericarditis, but low-dose steroids also conferred lower odds of recurrence compared to
206 high-dose steroids (OR 0.29, 95% CI 0.13, 0.66).²⁶ In the Hopkins Lupus cohort, we observed a
207 dose-related effect of oral prednisone treatment on the risk of pericarditis recurrence similar to
208 that in the general population, which was confirmed in the multivariate analysis. This suggests
209 that oral prednisone should be avoided whenever possible in patients with SLE and a history of
210 pericarditis. Further studies will be needed to understand the role of colchicine and IL-1-blocking
211 antibodies in treating recurrent pericarditis in SLE patients.

212 The use of the SLEDAI criteria to diagnose pericarditis is a limitation of this study. The
213 SLEDAI definition of pericarditis is, in fact, less stringent than that used by cardiology
214 associations, such as the European Society of Cardiology (ESC).^{18,22} According to the SLEDAI
215 definition, only one of the following criteria is necessary to be present for diagnosis: (1)
216 pericardial pain, (2) auscultation of pericardial rub, (3) presence of pericardial effusion on
217 imaging, and (4) EKG confirmation.^{17,18} Within our study cohort, patient-reported pericardial
218 chest pain was used most often to diagnose pericarditis. Importantly, we found that all patients (n
219 = 20) who were further evaluated via modalities, including TTE, CT chest imaging, or EKG,
220 demonstrated findings indicative of pericarditis, thereby fulfilling both SLEDAI and ESC criteria
221 for the diagnosis of pericarditis. This suggests that clinical criteria alone may be a robust tool for
222 diagnosing pericarditis among patients with SLE.

223 To conclude, our study describes the rate of recurrent pericarditis among patients with
224 SLE and describes risk factors associated with recurrence. Our data suggests that, despite the
225 common practice to use prednisone to treat SLE flares, the use of oral corticosteroids should be
226 avoided for those with a recent history of pericarditis. Future studies within this unique
227 population will be needed to determine the most effective treatment method for pericarditis, the
228 most common cardiac complication of systemic lupus erythematosus.

229

230 **ACKNOWLEDGMENTS**

231 Author contributions: Drs. Luigi Adamo and Andrea Fava had full access to all the data in the
232 study and took responsibility for the integrity of the data and the accuracy of the data analysis.
233 Study concept and design: Luigi Adamo, Andrea Fava, and Michelle Petri. Acquisition, analysis,
234 and interpretation of data: Yoo Jin Kim, Jana Lovell, Alaa Diab, Laurence S. Magder, Daniel
235 Goldman, Michelle Petri, Andrea Fava, and Luigi Adamo. Drafting of the manuscript: Yoo Jin
236 Kim, Jana Lovell, Luigi Adamo, and Andrea Fava. Critical revision of the manuscript for
237 important intellectual content: Yoo Jin Kim, Jana Lovell, Laurence S. Magder, Daniel Goldman,
238 Michelle Petri, Andrea Fava, and Luigi Adamo. Statistical analysis: Laurence S. Magder.

239

240 Funding/support: This study was supported in part by NHLBI grants 5K08HLO145108-03 and
241 1R01HL160716-01, awarded to Dr. Luigi Adamo, and NHLBI grant T32-HL007227, awarded to
242 Dr. Jana Lovell. The Hopkins Lupus Cohort is supported by R01DK134625, awarded to Dr.
243 Andrea Fava.

244

245 Financial disclosures: The authors have no financial disclosures immediately relevant to this
246 manuscript to disclose. Dr. Adamo discloses the following other relationships: consultant for
247 Kiniksa Pharmaceutical and co-founder of i-Cordis, LLC, a start-up company focused on
248 developing immunomodulatory small molecules to treat heart failure. All the other authors have
249 no financial interests to report.

250

251 **REFERENCES**

- 252 1. Man BL, Mok CC. Serositis related to systemic lupus erythematosus: prevalence and
253 outcome. *Lupus*. 2005;14(10):822-6. doi:10.1191/0961203305lu2187oa
- 254 2. Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus
255 erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort
256 of 1,000 patients. *Medicine (Baltimore)*. Sep 2003;82(5):299-308.
257 doi:10.1097/01.md.0000091181.93122.55
- 258 3. Ryu S, Fu W, Petri MA. Associates and predictors of pleurisy or pericarditis in SLE.
259 *Lupus Sci Med*. 2017;4(1):e000221. doi:10.1136/lupus-2017-000221
- 260 4. Chiabrando JG, Bonaventura A, Vecchie A, et al. Management of Acute and Recurrent
261 Pericarditis: JACC State-of-the-Art Review. *J Am Coll Cardiol*. Jan 7 2020;75(1):76-92.
262 doi:10.1016/j.jacc.2019.11.021
- 263 5. Caforio AL, Brucato A, Doria A, et al. Anti-heart and anti-intercalated disk
264 autoantibodies: evidence for autoimmunity in idiopathic recurrent acute pericarditis. *Heart*. May
265 2010;96(10):779-84. doi:10.1136/hrt.2009.187138
- 266 6. Marcolongo R, Russo R, Laveder F, Noventa F, Agostini C. Immunosuppressive therapy
267 prevents recurrent pericarditis. *J Am Coll Cardiol*. Nov 1 1995;26(5):1276-9. doi:10.1016/0735-
268 1097(95)00302-9
- 269 7. Imazio M, Trincheri R, Shabeti R. Pathogenesis, management, and prevention of
270 recurrent pericarditis. *J Cardiovasc Med (Hagerstown)*. Jun 2007;8(6):404-10.
271 doi:10.2459/01.JCM.0000269708.72487.34

- 272 8. Cantarini L, Imazio M, Brizi MG, et al. Role of autoimmunity and autoinflammation in
273 the pathogenesis of idiopathic recurrent pericarditis. *Clin Rev Allergy Immunol*. Feb
274 2013;44(1):6-13. doi:10.1007/s12016-010-8219-x
- 275 9. Lo Presti S, Elajami TK, Reyalde R, Anthony C, Imazio M, Klein AL. Emerging
276 Therapies for Recurrent Pericarditis: Interleukin-1 inhibitors. *J Am Heart Assoc*. Oct 5
277 2021;10(19):e021685. doi:10.1161/JAHA.121.021685
- 278 10. Klein AL, Imazio M, Cremer P, et al. Phase 3 Trial of Interleukin-1 Trap Riloncept in
279 Recurrent Pericarditis. *N Engl J Med*. Jan 7 2021;384(1):31-41. doi:10.1056/NEJMoa2027892
- 280 11. Ostendorf B, Iking-Konert C, Kurz K, Jung G, Sander O, Schneider M. Preliminary
281 results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with
282 severe lupus arthritis. *Ann Rheum Dis*. Apr 2005;64(4):630-3. doi:10.1136/ard.2004.025858
- 283 12. Cacoub P, Marques C. Acute recurrent pericarditis: from pathophysiology towards new
284 treatment strategy. *Heart*. Jul 2020;106(14):1046-1051. doi:10.1136/heartjnl-2019-316481
- 285 13. Brucato A, Imazio M, Gattorno M, et al. Effect of Anakinra on Recurrent Pericarditis
286 Among Patients With Colchicine Resistance and Corticosteroid Dependence: The AIRTRIP
287 Randomized Clinical Trial. *JAMA*. Nov 8 2016;316(18):1906-1912.
288 doi:10.1001/jama.2016.15826
- 289 14. Myachikova VY, Maslyanskiy AL, Moiseeva OM, et al. Treatment of Idiopathic
290 Recurrent Pericarditis With Goflikcept: Phase II/III Study Results. *J Am Coll Cardiol*. Jul 4
291 2023;82(1):30-40. doi:10.1016/j.jacc.2023.04.046
- 292 15. Fangtham M, Petri M. 2013 update: Hopkins lupus cohort. *Curr Rheumatol Rep*. Sep
293 2013;15(9):360. doi:10.1007/s11926-013-0360-0

- 294 16. Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the
295 Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage
296 index for systemic lupus erythematosus. *Arthritis Rheum.* Mar 1996;39(3):363-9.
297 doi:10.1002/art.1780390303
- 298 17. Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with
299 systemic lupus erythematosus. *N Engl J Med.* Dec 15 2005;353(24):2550-8.
300 doi:10.1056/NEJMoa051135
- 301 18. Adler Y, Charron P, Imazio M, et al. 2015 ESC Guidelines for the diagnosis and
302 management of pericardial diseases: The Task Force for the Diagnosis and Management of
303 Pericardial Diseases of the European Society of Cardiology (ESC) Endorsed by: The European
304 Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J.* Nov 7 2015;36(42):2921-2964.
305 doi:10.1093/eurheartj/ehv318
- 306 19. D'Agostino RB, Lee ML, Belanger AJ, Cupples LA, Anderson K, Kannel WB. Relation
307 of pooled logistic regression to time dependent Cox regression analysis: the Framingham Heart
308 Study. *Stat Med.* Dec 1990;9(12):1501-15. doi:10.1002/sim.4780091214
- 309 20. Fava A, Petri M. Systemic lupus erythematosus: Diagnosis and clinical management. *J*
310 *Autoimmun.* Jan 2019;96:1-13. doi:10.1016/j.jaut.2018.11.001
- 311 21. Fava A, Cammarata M, Adamo L. Riloncept use in lupus pericarditis. *Clin Exp*
312 *Rheumatol.* Mar 19 2024;doi:10.55563/clinexprheumatol/pb3hzb
- 313 22. Fanouriakis A, Kostopoulou M, Andersen J, et al. EULAR recommendations for the
314 management of systemic lupus erythematosus: 2023 update. *Ann Rheum Dis.* Jan 2
315 2024;83(1):15-29. doi:10.1136/ard-2023-224762

- 316 23. Kallas R, Li J, Petri M. Predictors of Osteonecrosis in Systemic Lupus Erythematosus: A
317 Prospective Cohort Study. *Arthritis Care Res (Hoboken)*. Jul 2022;74(7):1122-1132.
318 doi:10.1002/acr.24541
- 319 24. Imazio M, Belli R, Brucato A, et al. Efficacy and safety of colchicine for treatment of
320 multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled,
321 randomised trial. *Lancet*. Jun 28 2014;383(9936):2232-7. doi:10.1016/S0140-6736(13)62709-9
- 322 25. Imazio M, Brucato A, Cemin R, et al. A randomized trial of colchicine for acute
323 pericarditis. *N Engl J Med*. Oct 17 2013;369(16):1522-8. doi:10.1056/NEJMoa1208536
- 324 26. Lotrionte M, Biondi-Zoccai G, Imazio M, et al. International collaborative systematic
325 review of controlled clinical trials on pharmacologic treatments for acute pericarditis and its
326 recurrences. *Am Heart J*. Oct 2010;160(4):662-70. doi:10.1016/j.ahj.2010.06.015

327

328

329

330

331

332 TABLES AND FIGURES

Table 1. Demographics and Clinical Characteristics of Patients with Pericarditis in the Hopkins Lupus Cohort

	All (N = 590)
Age at first episode of pericarditis (years), no. (%)	
< 30	257 (44)
30-44	208 (35)
45-59	102 (17)
≥ 60	23 (4)
Female sex, no. (%)	535 (91)
Race, no. (%)	
White	253 (43)
Black	303 (51)
Other	34 (6)
Onset of pericarditis, no. (%)	
< 1990	106 (18)
1990 – 1999	165 (28)
2000 – 2009	215 (36)
≥ 2010	104 (18)
Duration of follow-up after onset of pericarditis (person-years), no. (%)	
< 5	260 (44)
5 – 10	115 (19)
10 – 15	91 (15)
15 – 20	55 (9)
≥ 20	69 (12)
Recurrent episodes of pericarditis, no. (%)	
1	61 (10)
2 – 4	46 (8)
5 – 12	13 (2)

Table 2. Rates of recurrent pericarditis by demographic, clinical, and treatment characteristics

Exposure	Events, no.	Rate, per person-years	Rate ratio (95% CI)	P-value
Demographic characteristics				
Age group, years				
18-39*	171	0.085	1.0 (Ref)	NA
40-49	74	0.054	0.58 (0.37,0.90)	0.016
50-59	28	0.025	0.25 (0.12,0.53)	<.001
≥60	5	0.006	0.05 (0.01,0.18)	<.001
Sex				
Female*	260	0.054	1.0 (Ref)	NA
Male	18	0.038	0.43 (0.11,1.69)	0.228
Race				
White*	67	0.045	1.0 (Ref)	NA
Black	172	0.061	1.72 (0.99,2.97)	0.054
Other	9	0.032	0.90 (0.34,2.34)	0.827
Year of onset of pericarditis				
Before 2000*	71	0.082	1.0 (Ref)	NA
2000 – 2009	98	0.055	0.59 (0.39,0.89)	0.011
After 2010	109	0.042	0.36 (0.22,0.61)	<.001
Clinical characteristics				
Time from initial episode				
<1*	48	0.212	1.0 (Ref)	NA
1-3	59	0.105	0.50 (0.32,0.79)	0.003
3-10	91	0.048	0.21 (0.14,0.32)	<.001
≥10	80	0.031	0.12 (0.06,0.23)	<.001
Most recent past clinical findings				
Disease activity, SLEDAI				
0*	52	0.032	1.0 (Ref)	NA
1-2	58	0.043	1.32 (0.92,1.89)	0.130
≥10	156	0.088	2.34 (1.65,3.30)	<.001
Low C3				
Normal*	79	0.075	1.0 (Ref)	NA
Low C4	190	0.048	0.54 (0.37,0.78)	0.001
Normal*	75	0.098	1.0 (Ref)	NA
Anti-dsDNA seropositive				
Seronegative*	127	0.041	1.0 (Ref)	NA
History of various conditions				
Anti-SM seropositive				
Seronegative*	75	0.049	1.0 (Ref)	NA
Proteinuria				
No history*	146	0.069	1.0 (Ref)	NA
Nephrotic syndrome	34	0.028	0.47 (0.27,0.82)	0.008
No history*	242	0.06	1.0 (Ref)	NA
Pulmonary fibrosis				
No history*	227	0.051	1.0 (Ref)	NA
Pulmonary hypertension				
No history*	252	0.058	1.0 (Ref)	NA
Hemolytic anemia				
No history*	242	0.055	1.0 (Ref)	NA
Lymphadenopathy				
No history*	158	0.053	1.0 (Ref)	NA
Raynaud syndrome				
Not present*	146	0.074	1.0 (Ref)	NA
Current Treatment characteristics				
Prednisone, mg/day				
0*	98	0.045	1.0 (Ref)	NA
1-9	79	0.052	1.54 (0.85,2.79)	0.154
10-19	45	0.076	2.23 (1.25,4.00)	0.007
≥20	216	0.063	3.92 (2.31,6.63)	<.001
Hydroxychloroquine use				
Not present*	112	0.058	1.0 (Ref)	NA
Immunosuppressant use				
Not present*	166	0.059	0.92 (0.62,1.36)	0.678

* Reference rate for determination of rate ratio for the recurrence of pericarditis

334 **Figure 1.** Results of multivariate analyses demonstrating predictors of recurrent pericarditis
335 among patients with SLE. Reference rates for the determination rate ratios are summarized in
336 Table 2.

Predictors of recurrent pericarditis

